Granules India announced that the 33th Annual General Meeting(AGM) of the company will be held on 6 August 2024.Powered by Capital Market - Live News

Net profit of Granules India rose 8.39% to Rs 129.65 crore in the quarter ended March 2024 as against Rs 119.61 crore during the previous quarter ended March 2023. Sales declined 1.65% to Rs 1175.78 crore in the quarter ended March 2024 as against Rs 1195.50 crore during the previous quarter ended March 2023.For the full year,net profit declined 21.54% to Rs 405.31 crore in the year ended March 2024 as against Rs 516.60 crore during the previous year ended March 2023. Sales declined 0.12% to Rs 4506.37 crore in the year ended March 2024 as against Rs 4511.92 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales1175.781195.50 -2 4506.374511.92 0 OPM %21.7519.08 -18.9920.25 - PBDT228.82212.69 8 754.56871.67 -13 PBT175.64163.99 7 547.23687.17 -20 NP129.65119.61 8 405.31516.60 -22 Powered by Capital Market - Live News

Granules India announced that the Board of Directors of the Company at its meeting held on 15 May 2024, has recommended a Final dividend of Rs.1.50 per share (i.e.150%), subject to the approval of the shareholders.Powered by Capital Market - Live News

Granules India will hold a meeting of the Board of Directors of the Company on 15 May 2024.Powered by Capital Market - Live News

Granules India announced today that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA), filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the Company, for Colchicine Capsules, 0.6 mg. It is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Mitigare Capsules, 0.6 mg of Hikma International Pharmaceuticals LLC (Hikma).Colchicine Capsules are indicated for prophylaxis of gout flares in adults. Granules now have a total of 64 ANDA approvals from the US FDA (63 Final approvals and 1 tentative approvals).The current annual U.S. market for Colchicine Capsules is approximately $55 Million, according to MAT Feb 2024, IQVIA/IMS Health.Powered by Capital Market - Live News